How Is Tachycardia Treated: From Drugs to Ablation

Treatment for tachycardia spans a wide range, from simple physical maneuvers you can do at home to medications, catheter-based procedures, implanted devices, and open-heart surgery. Which option fits depends on the type of fast heart rhythm, how dangerous it is, how often it recurs, and the patient’s overall health. The landscape has changed substantially in recent years with the arrival of newer ablation energy sources and machine-learning tools that help pinpoint where abnormal electrical signals originate.

What Happens in the First Few Minutes

When a sudden episode of supraventricular tachycardia (SVT) hits, the first-line response is often a vagal maneuver. The classic version is the Valsalva maneuver: you bear down hard, as if straining on the toilet, to raise pressure inside the chest and stimulate the vagus nerve, which slows conduction through the heart. A modified version adds a step where you immediately lie flat and have someone raise your legs after the strain. This leg-raise modification roughly doubles the chance of converting the rhythm back to normal compared with the standard technique, with no increase in side effects.¹ The mechanism is straightforward: the strain raises thoracic pressure, and the sudden leg elevation pushes extra blood back to the heart, together boosting left atrial pressure and triggering the baroreceptor reflex that slows the heart.² This works in children too: in a pediatric trial, over half of children who received the modified technique converted within five minutes, compared with about a third using the standard approach.³

If vagal maneuvers fail, the next step in the emergency room is usually intravenous adenosine, a drug that briefly blocks electrical conduction at the atrioventricular (AV) node. In a large multicenter study of over 1,200 SVT episodes treated before hospital arrival, adenosine successfully restored normal rhythm in about 80% of cases.⁴ For patients who are hemodynamically unstable, meaning their blood pressure is dangerously low or they are showing signs of shock, electrical cardioversion (a synchronized shock to the chest) is the go-to treatment. In those unstable patients, electrical cardioversion had more than twice the odds of success compared with adenosine.⁴

Medications for Ongoing Rate and Rhythm Control

Once the acute episode is over, you may need daily medication to keep tachycardia from coming back or to keep the heart rate within a safe range. Beta-blockers and calcium channel blockers are the workhorses for rate control, particularly in atrial fibrillation. Both drug classes achieve target resting heart rates at comparable rates: in one head-to-head comparison, about 92% of patients on either drug class reached a resting rate below 110 beats per minute. The practical difference shows up in side effects. Beta-blockers cause excessive slowing during normal sinus rhythm roughly twice as often as calcium channel blockers do.⁵ That matters if you swing between fast and normal rhythms, because a drug that controls your fast rate should not leave you feeling dizzy or exhausted when your rhythm is normal.

For rhythm control, meaning the goal is to prevent episodes entirely rather than just slow the rate, doctors use antiarrhythmic drugs like flecainide, sotalol, propafenone, or amiodarone. Amiodarone is generally the most effective of the group, but recurrence rates are still substantial. Across studies, about 35% of patients on amiodarone had atrial fibrillation come back within roughly 16 months, and patients on sotalol or propafenone fared worse, with recurrence rates as high as 63%.⁶ Amiodarone also carries a well-known risk of organ toxicity affecting the thyroid, lungs, and liver with long-term use, which limits its appeal in younger patients who would need it for decades.

For a condition called inappropriate sinus tachycardia, where the heart runs fast without a clear cardiac electrical problem, ivabradine has emerged as a useful option. Ivabradine selectively slows the sinus node without lowering blood pressure, and it has shown advantages over beta-blockers in this specific population.⁷

Catheter Ablation and Energy Sources

Catheter ablation is a minimally invasive procedure where thin wires are threaded through blood vessels into the heart, and targeted energy destroys the small areas of tissue that generate or sustain the abnormal rhythm. For many types of tachycardia, ablation is not just an option of last resort but a potential cure.

In Wolff-Parkinson-White syndrome (WPW) and other forms of SVT that rely on an extra electrical pathway, radiofrequency (RF) ablation achieves a pooled success rate of about 94%, with recurrence around 6% and a complication rate near 1%.⁸ For ventricular tachycardia (VT), especially in patients with structural heart disease who have implantable defibrillators, ablation has been shown to reduce VT recurrence and the frequency of painful shocks from those devices.⁹

Atrial fibrillation ablation is more complex. The standard approach, called pulmonary vein isolation, creates rings of scar tissue around the pulmonary veins to block the erratic electrical signals that typically trigger the arrhythmia. In a randomized trial of patients with persistent atrial fibrillation, adding posterior wall isolation on top of standard pulmonary vein isolation did not improve outcomes; about 53% of patients in both groups remained free of recurrent arrhythmia at one year without antiarrhythmic drugs.¹⁰ That roughly 50% success rate at one year for persistent atrial fibrillation is a reminder that ablation is not always a one-and-done solution for AF; repeat procedures are common.

Cryoballoon vs. Radiofrequency

Two thermal energy sources dominate catheter ablation today. Radiofrequency uses heat delivered through a catheter tip. Cryoballoon ablation uses an inflatable balloon cooled to very low temperatures to freeze tissue. A meta-analysis comparing the two for atrial fibrillation found no meaningful difference in freedom from arrhythmia at 12 months or longer.¹¹ The trade-off lies in the complication profile: cryoballoon ablation carries about a tenfold higher risk of phrenic nerve injury, which can temporarily paralyze one side of the diaphragm, compared with radiofrequency.¹¹ Most phrenic nerve injuries resolve on their own, but this is a real consideration when choosing between the two.

Pulsed-Field Ablation

Pulsed-field ablation (PFA) is the newest entrant. Rather than heating or freezing tissue, PFA uses rapid electrical pulses to punch permanent holes in cell membranes, a process called irreversible electroporation. The key advantage is tissue selectivity: heart muscle cells are more vulnerable to these pulses than the esophagus, blood vessels, and nerves nearby, which should lower the risk of collateral damage.¹² Early clinical data are encouraging. In a multicenter Chinese trial of PFA for SVT, acute success was above 99%, and only five of 158 patients had recurrence during six months of follow-up. No permanent heart block or other serious adverse events occurred.¹³ Longer follow-up and larger randomized trials comparing PFA head-to-head with RF and cryoablation are still underway.

What Can Go Wrong With Ablation

Catheter ablation is broadly safe, but it is not risk-free. The overall rate of peri-procedural complications sits around 3%, a figure that includes vascular access problems, cardiac perforation, blood clots, heart block, and, very rarely, death at a rate between about one and three per thousand procedures.¹⁴

The most feared complication of atrial fibrillation ablation is an atrioesophageal fistula, an abnormal connection between the left atrium and the esophagus that sits just behind it. Even when recognized and treated, mortality exceeds 30% in most case series.¹⁵ A systematic review found that overall mortality from esophageal-pericardial fistulas, including those arising from ablation, was about 38%, with a median time to death of 20 days.¹⁶ Prevention strategies during the procedure include using lower power settings, monitoring esophageal temperature, and physically deflecting the esophagus away from the ablation site.¹⁵ If PFA lives up to its promise of tissue selectivity, fistula rates may decline further, though the data are still young.

Surgical Approaches

When catheter ablation is not feasible or has failed, or when a patient is already undergoing open-heart surgery for another reason, surgical ablation becomes an option. The Cox-Maze procedure, now in its fourth iteration (CMP-IV), creates a deliberate pattern of scar lines across both atria to block the chaotic electrical circuits that drive atrial fibrillation. Long-term data from a single-center experience spanning over two decades show freedom from atrial fibrillation of about 93% at follow-up, with freedom from AF off antiarrhythmic drugs around 82%.¹⁷ Those numbers are substantially better than catheter-based ablation for persistent AF, though the comparison is not apples to apples because Cox-Maze is open-heart surgery with its own perioperative risks.

The durability is also impressive. In a study tracking outcomes out to a decade, freedom from arrhythmia off antiarrhythmic drugs at 10 years was about 60% for both stand-alone and concomitant Cox-Maze procedures.¹⁸ Patients who are cured by the procedure achieve a quality of life comparable to the general population.¹⁹

Implantable Defibrillators

For life-threatening ventricular tachycardia or ventricular fibrillation, an implantable cardioverter-defibrillator (ICD) acts as a safety net. It continuously monitors the heart rhythm and delivers a shock or rapid pacing burst to terminate dangerous episodes within seconds. ICDs do not prevent tachycardia from happening; they stop it once it starts, which is why they are often combined with drugs or ablation to reduce how often they need to fire. The 2025 ACC/AHA appropriate use criteria cover hundreds of clinical scenarios for ICDs, including primary prevention in patients at risk but who have not yet had a life-threatening arrhythmia, secondary prevention in those who have survived one, and newer device types like subcutaneous ICDs that avoid placing leads inside the heart.²⁰

Treatment During Pregnancy

Pregnancy adds layers of complexity because all antiarrhythmic drugs cross the placenta. For acute SVT, intravenous adenosine is considered safe in all three trimesters, including during labor. Atenolol and verapamil can be used for ongoing management in the second and third trimesters but are contraindicated in the first.²¹ Electrical cardioversion is safe throughout pregnancy, though there is a small risk of triggering preterm labor in the third trimester.²¹ Catheter ablation can be performed in selected pregnant patients using a zero-fluoroscopy approach to avoid radiation exposure, though it is generally reserved for drug-refractory cases.²²

Stroke Prevention Goes Hand in Hand With AF Treatment

Treating atrial fibrillation is not only about controlling the rhythm. AF creates sluggish blood flow in the atria that can form clots, leading to stroke. Risk-scoring systems help doctors decide who needs blood thinners. When the newer CHA₂DS₂-VASc score replaced the older CHADS₂ score, the proportion of patients flagged for anticoagulation jumped from about a third to over half, primarily because the updated score captures additional risk factors like vascular disease and female sex.²³ This matters because a sizeable group of women who appeared low-risk under the old system actually face meaningful stroke risk. The score also predicts overall mortality: higher scores track with higher rates of both stroke and death from any cause.²⁴ Even after a successful ablation, the decision to stop anticoagulation is nuanced and depends on your baseline stroke risk, not solely on whether the arrhythmia appears to be gone.

Monitoring After Ablation

Knowing whether an ablation actually worked requires monitoring, and the tools available for that have expanded beyond clinic-based Holter monitors. A study comparing consumer smartwatches to implantable cardiac monitors found that smartwatch algorithms detected AF recurrence with sensitivities between roughly 65% and 82%, which consistently outperformed traditional intermittent monitoring strategies like short-duration Holter recordings.²⁵ The correlation between smartwatch-estimated AF burden and the gold-standard implantable monitor exceeded 0.97 for all tested algorithms.²⁶ This does not mean a smartwatch replaces a doctor’s evaluation, but it does mean that patients who already own one of these devices have a surprisingly useful tool for tracking their rhythm between clinic visits.

Machine Learning in Ablation Planning

One of the trickiest parts of ventricular tachycardia ablation is finding exactly where the abnormal circuit lives. The traditional approach involves threading catheters through the heart to create detailed electrical maps, a process that can be long and imprecise. Research groups are now training machine-learning algorithms to predict ablation targets from those electrical signals. In a porcine model of heart attack-related VT, a random forest algorithm identified critical sites with about 81% sensitivity and 71% specificity based on signals recorded during normal rhythm.²⁷ Separate work has achieved even higher accuracy for localizing the origins of idiopathic ventricular arrhythmias using ECG data alone, reaching about 98% accuracy across 21 possible sites in a testing cohort.²⁸

Another approach uses deep learning to non-invasively localize VT exit sites from the surface 12-lead ECG or even the intracardiac signals recorded by a patient’s implanted defibrillator. In simulated data this platform localized VT origins to within about 10 millimeters on average, and it successfully agreed with the clinical ablation site in a real patient case.²⁹ These tools are still in early-stage validation, but the direction is clear: pre-procedure computational mapping could shorten ablation times and reduce the amount of tissue that needs to be destroyed by narrowing the target before a catheter ever enters the heart.

Understanding the Underlying Mechanisms

Not all fast heart rhythms are the same electrically, and the mechanism matters for treatment selection. The three main mechanisms behind ventricular tachycardia, for example, are reentry (an electrical signal looping in a circle through damaged tissue), abnormal automaticity (cells firing on their own when they should not), and triggered activity (extra beats launched by aftershocks of the preceding heartbeat).³⁰ Reentry is the most common culprit in patients with prior heart attacks, while automaticity may dominate in structurally normal hearts. Distinguishing between them usually requires an invasive electrophysiology study, but the distinction influences whether a patient is better served by drugs, ablation, or a device. Triggered activity, for instance, can sometimes be managed by treating the underlying cause, such as correcting an electrolyte imbalance or stopping a culprit medication, while reentrant circuits in scar tissue are often best dealt with by ablation.